{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:28:23Z","timestamp":1761514103269,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.yebeh.2017.09.008","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T17:16:56Z","timestamp":1510852616000},"page":"194-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users"],"prefix":"10.1016","volume":"78","author":[{"given":"Kerri A.","family":"Schoedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.09.008_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0010","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0025","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in three pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"year":"2017","series-title":"Guidance for industry: assessment of abuse potential of drugs","author":"Food and Drug Administration","key":"10.1016\/j.yebeh.2017.09.008_bb0035"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0040","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0269881109359095","article-title":"Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid","volume":"25","author":"Feltner","year":"2011","journal-title":"J Psychopharmacol"},{"year":"2010","series-title":"Guidance for industry: assessment of abuse potential of drugs","author":"Food and Drug Administration","key":"10.1016\/j.yebeh.2017.09.008_bb0045"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0050","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0055","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.clpt.6100492","article-title":"Assessing abuse liability during drug development: changing standards and expectations","volume":"83","author":"Schoedel","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/clpt.2010.67","article-title":"Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users","volume":"88","author":"Schoedel","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt1971122part1245","article-title":"Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man","volume":"12","author":"Martin","year":"1971","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/epi.13638","article-title":"Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"58","author":"Wood","year":"2017","journal-title":"Epilepsia"},{"year":"2012","series-title":"Fycompa (perampanel) [Full prescribing information]","author":"Eisai Inc.","key":"10.1016\/j.yebeh.2017.09.008_bb0075"},{"year":"2016","series-title":"Potiga (ezogabine) [Full prescribing information]","author":"GlaxoSmithKline","key":"10.1016\/j.yebeh.2017.09.008_bb0080"},{"year":"2014","series-title":"Vimpat (lacosamide) [Full prescribing information]","author":"UCB Inc.","key":"10.1016\/j.yebeh.2017.09.008_bb0085"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yebeh.2016.05.010","article-title":"Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: a Phase I randomized controlled trial","volume":"61","author":"Levy-Cooperman","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"14S","key":"10.1016\/j.yebeh.2017.09.008_bb0095","article-title":"Abuse potential of antiepileptic drugs: a review using the VigiBase\u2122 pharmacovigilance database","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/14740338.2013.796363","article-title":"Safety issues around misuse of antiepileptics","volume":"12","author":"Piskorska","year":"2013","journal-title":"Expert Opin Drug Saf"},{"year":"2015","series-title":"Neurontin (gabapentin) [full prescribing information]","author":"Pfizer Inc.","key":"10.1016\/j.yebeh.2017.09.008_bb0105"},{"year":"2016","series-title":"Lyrica (pregabalin) [full prescribing information]","author":"Pfizer Inc.","key":"10.1016\/j.yebeh.2017.09.008_bb0110"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3399\/bjgp12X653516","article-title":"Substance misuse of gabapentin","volume":"62","author":"Smith","year":"2012","journal-title":"Br J Gen Pract"},{"year":"2014","series-title":"Advice for prescribers on the risk of the misuse of pregabalin and gabapentin","author":"Public Health England, NHS England","key":"10.1016\/j.yebeh.2017.09.008_bb0120"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin: a systematic review","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males","volume":"66","author":"Rolan","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2017.09.008_bb0135","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males","volume":"63","author":"Sargentini-Maier","year":"2007","journal-title":"Br J Clin Pharmacol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017303086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017303086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:26:22Z","timestamp":1761503182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017303086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":27,"alternative-id":["S1525505017303086"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.09.008","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}